Plans

\label{plans}
We have a long backlog of features we plan to prioritize with post-launch feedback, such as new cohort and time visualizations, support for new data types, or access and scripting with R.
Our early conversations with investigators working on other diseases indicate that many of the study designs and even the assays are shared. That could make application to other diseases a matter of data access, metadata schemas, and domain partnership.
Another opportunity lies in multivariate or automated analysis. Having brought together and harmonized the data for investigator use, algorithmic pattern finding or hybrid approaches with investigator guidance could be interesting to pursue.
However, even great designs with proven potential can fail to achieve impact. VA of completed studies is not part of daily workflow and must find ways to connect to existing activities such as grants, papers, collaborations, and new data generation. To maximize domain impacts for users who are not professional analysts, we believe we must apply lessons from commercial product development suggesting that ease of use for new or infrequent users, change management through funding organizations, and effective outreach plans are major success factors.